Lupin will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live

The EIR was issued with an inspection classification of voluntary action indicated (VAI) post the inspection of the facility from 16 September to 27 September 2024. Nilesh Gupta, MD, Lupin said, 'We are pleased to receive the EIR from the US FDA for our Pithampur Unit-1 facility with a satisfactory VAI classification. This reflects our commitment to the highest standards of quality and compliance.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Lupin's consolidated net profit jumped 74.1% to Rs 852.63 crore on 11.3% increase in sales to Rs 5,497.01 crore in Q2 FY25 over Q2 FY24. Shares of Lupin rose 0.56% to currently trade at Rs 2,261 on the BSE.Powered by Capital Market - Live

Lupin today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1 manufacturing facility that manufactures both APIs and finished products. The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from 16 September to 27 September  2024.Powered by Capital Market - Live

Lupin has been marketing the Huminsulin range of products comprising of Insulin human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing distribution and promotion agreements with Lilly, India. The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. Nilesh Gupta, MD, Lupin, said, 'This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high-quality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care.' Commenting on the acquisition, Rajeev Sibal, President, India Region Formulations, Lupin said, 'Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Lupin's consolidated net profit jumped 74.1% to Rs 852.63 crore on 11.3% increase in sales to Rs 5,497.01 crore in Q2 FY25 over Q2 FY24. Shares of Lupin rose 0.28% to currently trade at Rs 2,316.10 on the BSE.Powered by Capital Market - Live

New Listing: Unimech Aerospace and Manufacturing will debut on the stock exchanges today. The IPO price band is fixed between Rs 745 and 785 per share. The issue opened between 23rd December 2024 and 26th December 2024. The issue was subscribed 175.31 times. Stocks to Watch: Lupin announced the acquisition of Huminsulin India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. CESC's subsidiary, Noida Power company, issued a letter of acceptance (LoA) to another subsidiary of the company, Purvah Green Power Private for supply of 300 MW wind-solar hybrid power on long- term basis. Jubilant Ingrevia's subsidiary, Jubilant Infrastructure (JIL) plans to acquire 6.67% stake in Forum I Aviation Private (FAPL) from Hero Fincorp & Sunil Kant Munjal. Post acquisition, JIL will hold 15.79% equity shares in FAPL. Shriram Properties announced strategic sale of around 3.9 acre land parcel in Chennai to a large healthcare and educational group in South India. Hindalco Industries secured Meenakshi Coal Mine in Odisha through vesting order by the Ministry of Coal. The Meenakshi coal mine, located in Odisha, is a fully explored block with a Peak Rated Capacity (PRC) of 12 million tonnes per annum and approximately 285.23 million tonnes of geological reserves. Falir Writing Industries' wholly-owned subsidiary, Flair Writing Equipments has incorporated a subsidiary company in the name and style of Flomaxe Stationery Private to carry on the business of manufacturing and distribution of stationery and other allied product.Powered by Capital Market - Live

Lupin Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 2276.25, up 2.17% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.03% on the day, quoting at 23805.25. The Sensex is at 78760.73, up 0.08%. Lupin Ltd has risen around 9.99% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has risen around 3.28% in last one month and is currently quoting at 23008.35, up 0.77% on the day. The volume in the stock stood at 9.18 lakh shares today, compared to the daily average of 8.3 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 2284.6, up 1.8% on the day. Lupin Ltd is up 73.38% in last one year as compared to a 9.49% spurt in NIFTY and a 37.53% spurt in the Nifty Pharma index.The PE of the stock is 33.91 based on TTM earnings ending September 24.Powered by Capital Market - Live

Lupin has allotted 36979 fully paid-up equity shares of Rs 2/- each. These shares have been allotted upon exercising of vested options granted to the employees under Stock Option plans of the Company. In view of the above, the issued and paid-up share capital of the Company has been increased to Rs 91,24,69,084 consisting of 45,62,34,542 equity shares of Rs 2/- each.Powered by Capital Market - Live

Emtricitabine and tenofovir alafenamide combination is used together with other medicines to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). This medicine is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection. The said drug is the generic equivalent of Descovy Tablets of Gilead Sciences, Inc. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity. This product will be manufactured at Lupin's Nagpur facility in India. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Lupin's consolidated net profit jumped 74.1% to Rs 852.63 crore on 11.3% increase in sales to Rs 5,497.01 crore in Q2 FY25 over Q2 FY24. Shares of Lupin shed 0.13% to currently trade at Rs 2,096 on the BSE.Powered by Capital Market - Live

GIBTULIO (empagliflozin), GIBTULIO MET (empagliflozin + metformin) and AJADUO (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease. Lupin has been marketing GIBTULIO and GIBTULIO MET since 2016, and AJADUO since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India. As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Nilesh Gupta, managing director, Lupin, said, 'Lupin has always been at the forefront of providing best-in-class quality healthcare solutions to patients. This acquisition is a key step in strengthening our diabetes portfolio and reaffirms our commitment to delivering innovative and cost-effective medications for patients across India.' Rajeev Sibal, President ' India Region Formulations, Lupin said, 'The increasing prevalence of diabetes and related lifestyle diseases calls for greater thrust on diabetes treatment and management, as well as accessibility of medicines for patients. This acquisition enables us to deliver effective and affordable treatment options to millions across India.' Lupin's consolidated net profit jumped 74.1% to Rs 852.63 crore on 11.3% increase in sales to Rs 5,497.01 crore in Q2 FY25 over Q2 FY24. The counter declined 1.95% to settle at Rs 2,075 on Friday, 13 December 2024Powered by Capital Market - Live

Lupin announced today the acquisition of anti-diabetes trademarks GIBTULIO', GIBTULIO MET' and AJADUO' from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), to strengthen its diabetes portfolio in the country. As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Lupin has been marketing GIBTULIO' and GIBTULIO MET' since 2016, and AJADUO' since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India. GIBTULIO' (empagliflozin), GIBTULIO MET' (empagliflozin + metformin) and AJADUO' (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.Powered by Capital Market - Live